文献速递淋巴瘤

芬维A胺联合利妥昔单抗治疗惰性B细胞淋巴瘤及套细胞淋巴瘤的I-II期研究结果

Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.
PubMed 文献 · Br J Haematol · 2017-01-05

本研究为芬维A胺联合利妥昔单抗治疗惰性B细胞非霍奇金淋巴瘤(B-NHL)或套细胞淋巴瘤的I-II期研究,共治疗32例患者(I期7例,II期25例)。未观察到剂量限制性毒性,II期部分6例(24%)患者出现缓解,中位缓解持续时间47个月(95%CI 2-56)。联合方案耐受性良好,总缓解率适中但缓解持续时间较长。

要点

  • 芬维A胺联合利妥昔单抗耐受性良好,未观察到剂量限制性毒性。
  • II期部分最常见≥3级治疗相关不良事件为皮疹(n=3)和中性粒细胞减少(n=3)。
  • II期部分6例(24%)患者缓解,中位缓解持续时间47个月(95%CI 2-56)。

核心结论

  • 芬维A胺联合利妥昔单抗耐受性良好,总缓解率适中,但缓解持续时间较长。
  • 进一步研究应聚焦于识别B-NHL中对治疗有反应的亚组人群。

研究设计与样本

  • I-II期研究,纳入惰性B-NHL或套细胞淋巴瘤患者。
  • I期设计为芬维A胺900 mg/m2口服每日两次,每7天周期第1-5天给药,采用降阶梯设计。
  • II期部分在芬维A胺基础上加用利妥昔单抗375 mg/m2静脉给药,第5-9周每周一次,之后每3个月一次。
  • 芬维A胺持续给药直至疾病进展或不耐受。
  • 共治疗32例患者:I期7例,II期25例。

主要发现

  • 未观察到剂量限制性毒性。
  • II期部分使用芬维A胺900 mg/m2每日两次联合利妥昔单抗。
  • 最常见≥3级治疗相关不良事件为皮疹(n=3)和中性粒细胞减少(n=3)。
  • II期部分6例(24%)患者出现缓解,中位缓解持续时间47个月(95%CI 2-56)。

局限性

  • 进一步研究应聚焦于识别B-NHL中对治疗有反应的亚组人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I-II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mantle cell lymphoma. The phase I design de-escalated from fenretinide at 900 mg/m2 PO BID for days 1-5 of a 7-day cycle. The phase II portion added 375 mg/m2 IV rituximab weekly on weeks 5-9 then every 3 months. Fenretinide was continued until progression or intolerance. Thirty-two patients were treated: 7 in phase I, and 25 in phase II of the trial. No dose-limiting toxicities were observed. The phase II component utilized fenretinide 900 mg/m2 twice daily with rituximab. The most common treatment-related adverse events of grade 3 or higher were rash (n = 3) and neutropenia (n = 3). Responses were seen in 6 (24%) patients on the phase II study, with a median duration of response of 47 months (95% confidence interval, 2-56). The combination of fenretinide and rituximab was well tolerated, yielded a modest overall response rate, but with prolonged remission durations. Further study should focus on identifying the responsive subset of B-NHL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cowan AJ, Stevenson PA, Gooley TA, et al. Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. Br J Haematol. 2017. PMID: 28055107. doi:10.1111/bjh.14451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。